GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (NAS:KZR) » Definitions » ROA %

Kezar Life Sciences (Kezar Life Sciences) ROA % : -54.85% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Kezar Life Sciences's annualized Net Income for the quarter that ended in Dec. 2023 was $-129.04 Mil. Kezar Life Sciences's average Total Assets over the quarter that ended in Dec. 2023 was $235.28 Mil. Therefore, Kezar Life Sciences's annualized ROA % for the quarter that ended in Dec. 2023 was -54.85%.

The historical rank and industry rank for Kezar Life Sciences's ROA % or its related term are showing as below:

KZR' s ROA % Range Over the Past 10 Years
Min: -78.69   Med: -31.96   Max: -25.95
Current: -38.65

During the past 8 years, Kezar Life Sciences's highest ROA % was -25.95%. The lowest was -78.69%. And the median was -31.96%.

KZR's ROA % is ranked worse than
52.38% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs KZR: -38.65

Kezar Life Sciences ROA % Historical Data

The historical data trend for Kezar Life Sciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences ROA % Chart

Kezar Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -34.37 -34.59 -29.55 -26.37 -39.12

Kezar Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.07 -30.42 -35.51 -36.05 -54.85

Competitive Comparison of Kezar Life Sciences's ROA %

For the Biotechnology subindustry, Kezar Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kezar Life Sciences's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's ROA % distribution charts can be found below:

* The bar in red indicates where Kezar Life Sciences's ROA % falls into.



Kezar Life Sciences ROA % Calculation

Kezar Life Sciences's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-101.87/( (299.568+221.235)/ 2 )
=-101.87/260.4015
=-39.12 %

Kezar Life Sciences's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-129.04/( (249.326+221.235)/ 2 )
=-129.04/235.2805
=-54.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Kezar Life Sciences  (NAS:KZR) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-129.04/235.2805
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-129.04 / 0)*(0 / 235.2805)
=Net Margin %*Asset Turnover
=N/A %*0
=-54.85 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Kezar Life Sciences ROA % Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kezar Life Sciences (Kezar Life Sciences) Business Description

Traded in Other Exchanges
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.
Executives
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Nicholas Michael Mordwinkin officer: Chief Business Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Wallace Courtney director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Micki Klearman director C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Equal Talent Investments Ltd 10 percent owner THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000
Noreen Henig officer: Chief Medical Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
John Franklin Fowler director, officer: CEO C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Christopher J. Kirk director, officer: President and CSO C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Belsky officer: Chief Financial Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Vassiliki Economides officer: SVP, Strategy & External Aff. C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Elizabeth Garner director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Gp, Llc 10 percent owner 100 HIGH STREET, SUITE 1105, BOSTON DC 02110
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111